The Impact of Antidiabetic Agents on Sarcopenia in Type 2 Diabetes: A Literature Review
| Autor: | Kai-Jen Tien, Chen-Ning Wu |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Sarcopenia
Endocrinology Diabetes and Metabolism Review Article Type 2 diabetes Bioinformatics Diseases of the endocrine glands. Clinical endocrinology Endocrinology Diabetes mellitus Humans Hypoglycemic Agents Medicine In patient Muscle Skeletal Wasting Antidiabetic agents business.industry Poor glycemic control Type 2 Diabetes Mellitus RC648-665 musculoskeletal system medicine.disease body regions Diabetes Mellitus Type 2 medicine.symptom business human activities |
| Zdroj: | Journal of Diabetes Research Journal of Diabetes Research, Vol 2020 (2020) |
| ISSN: | 2314-6753 2314-6745 |
| Popis: | Sarcopenia is a geriatric syndrome characterized by decline of skeletal muscle mass and function. Contributing factors include nutritional, genetic, inflammatory, and endocrinal factors. The reported prevalence of sarcopenia in type 2 diabetes mellitus is high, especially in patients with poor glycemic control. Additionally, antidiabetic agents may alter the balance between protein synthesis and degradation through various mechanisms of skeletal muscle mass regulation. This study reviewed the literature on the pathogenesis of sarcopenia in diabetes mellitus and the current understanding of whether antidiabetic agents contribute positively or negatively to sarcopenia and muscle wasting. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |